---
title: "Varegacestat (AL102) in Desmoid tumors: Product comparison"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Product comparison. Topics: Dosing, dosing frequency, and form: varegacestat in RINGSIDE Part B; Dosage form: varegacestat capsule formulations; Dosing, dosing frequency, and form: nirogacestat; Dosing, dosing frequency, and form: sorafenib in the phase 3 desmoid tumor trial; 14 further topics. 18 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/product-comparison"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Dosing, dosing frequency, and form: varegacestat in RINGSIDE Part B

> “Varegacestat (VAR) is an investigational, once daily, oral gamma secretase inhibitor that previously showed antitumor activity in pts with DT in the RINGSIDE Phase 2 study.”
> “156 pts were randomized 1:1 to once daily oral VAR 1.2 mg (n=79) or PBO (n=77).”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-2.1.2.14-2"></a>

### Dosage form: varegacestat capsule formulations

> “This is an open-label, randomized, crossover study to evaluate the relative bioavailability (rBA) and bioequivalence (BE) of a test capsule formulation of varegacestat compared to reference capsules formulation under fasting conditions.”

Source: [ClinicalTrials.gov NCT07610005](https://clinicaltrials.gov/study/NCT07610005)

<a id="topic-2.1.2.14-3"></a>

### Dosing, dosing frequency, and form: nirogacestat

> “OGSIVEO® (nirogacestat) tablets, for oral use”
> “The recommended dosage of OGSIVEO is 150 mg administered orally twice daily until disease progression or unacceptable toxicity. OGSIVEO may be taken with or without food.”
> “Tablets: 100 mg, and 150 mg. (3)”
> “One blister card with 14 tablets”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

### Dosing, dosing frequency, and form: sorafenib in the phase 3 desmoid tumor trial

> “In this double-blind, phase 3 trial, we randomly assigned 87 patients with progressive, symptomatic, or recurrent desmoid tumors to receive either sorafenib (400-mg tablet once daily) or matching placebo.”
> “Dose interruptions (of up to 28 days) and one dose reduction (to 200 mg once daily) were permitted and described in the trial protocol.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

<a id="topic-2.1.2.14-5"></a>

### Half-life: BMS-986115 (varegacestat) in the phase 1 trial

> “Following multiple once daily dose administration of BMS-986115, the median half-life ranged from 17.24 h to 28.01 h.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.2.14-6"></a>

### Half-life: company claim for varegacestat relative to nirogacestat

> “Varegacestat is a Gamma Secretase Inhibitor with a Differentiated Pharmacokinetic Profile”
> “78% Longer Half-Life than Nirogacestat”
> “(3) Immunome data on file”
> “1.2 mg Once Daily”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.1.2.14-7"></a>

### Half-life: nirogacestat

> “Terminal elimination half-life (t1/2)”
> “23 (37) hr”
> “Time to steady-state”
> “Approximately 6 days”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

### Phase 3 efficacy: varegacestat in RINGSIDE Part B

> “As of Oct 7, 2025, median duration of exposure was 20.3 months (range 0.8 – 34.6) for VAR and 11.1 months (range 0.2 – 34.6) for PBO.”
> “VAR demonstrated significantly better PFS compared with PBO (hazard ratio [HR]: 0.16 [95% CI: 0.07, 0.38; P<0.0001]).”
> “ORR was significantly better with VAR vs PBO (55.7% vs 9.1%; P<0.0001), with 3 CRs in the VAR arm and 1 CR in the PBO arm.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-2.1.2.14-9"></a>

### Phase 3 efficacy: nirogacestat in DeFi

> “The efficacy of OGSIVEO was evaluated in DeFi (NCT03785964), an international, multicenter, randomized (1:1), double-blind, placebo-controlled trial in 142 adult patients with progressing desmoid tumors not amenable to surgery.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

| DeFi outcome | OGSIVEO (N = 70) | Placebo (N = 72) |
| --- | --- | --- |
| Patients with a progression-free survival event, n (%) | “12 (17)” | “37 (51)” |
| Median progression-free survival, months (95% CI) | “NR (NR, NR)” | “15.1 (8.4, NR)” |
| Objective response rate, n (%) | “29 (41)” | “6 (8)” |
| Objective response rate, 95% CI | “(29.8, 53.8)” | “(3.1, 17.3)” |
| Complete response, n (%) | “5 (7)” | “0” |
| Partial response, n (%) | “24 (34)” | “6 (8)” |

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

> “Hazard ratio (95% CI)”
> “0.29 (0.15, 0.55)”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

### Phase 3 efficacy: sorafenib

> “With a median follow-up of 27.2 months, the 2-year progression-free survival rate was 81% (95% confidence interval [CI], 69 to 96) in the sorafenib group and 36% (95% CI, 22 to 57) in the placebo group (hazard ratio for progression or death, 0.13; 95% CI, 0.05 to 0.31; P<0.001).”
> “Before crossover, the objective response rate was 33% (95% CI, 20 to 48) in the sorafenib group and 20% (95% CI, 8 to 38) in the placebo group.”
> “The primary end point was investigator-assessed progression-free survival; rates of objective response and adverse events were also evaluated.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

<a id="topic-2.1.2.14-11"></a>

### Phase 3 safety: varegacestat in RINGSIDE Part B

> “Overall, 95% of adverse events (AEs) were Grade 1-2 and there were no Grade 5 AEs. Grade 3/4 AEs were reported in 57% of VAR pts and 17% of PBO pts. AEs led to dose reduction in 63 (80%) VAR pts and 7 (9%) PBO pts; 16 (20%) VAR pts and 5 (7%) PBO pts discontinued due to AEs. In the VAR arm, the most frequently reported AEs were diarrhea (82%), fatigue (44%), and rash (43%).”
> “Ovarian toxicity occurred in 20/36 (56%) premenopausal women on VAR, resolved in 11/20 (55%), and did not lead to dose interruption or drug withdrawal.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-2.1.2.14-12"></a>

### Phase 3 safety: nirogacestat in DeFi

> “In DeFi, diarrhea occurred in 84% of patients treated with OGSIVEO, and included Grade 3 events in 16% of patients.”
> “Serious adverse reactions occurred in 20% of patients who received OGSIVEO.”
> “Permanent discontinuation of OGSIVEO due to an adverse reaction occurred in 20% of patients.”
> “Dosage interruptions of OGSIVEO due to an adverse reaction occurred in 51% of patients.”
> “Dose reductions of OGSIVEO due to an adverse reaction occurred in 42% of patients.”

Source: [SpringWorks OGSIVEO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217677s009lbl.pdf)

> “Frequent adverse events with nirogacestat included diarrhea (in 84% of the patients), nausea (in 54%), fatigue (in 51%), hypophosphatemia (in 42%), and maculopapular rash (in 32%); 95% of adverse events were of grade 1 or 2. Among women of childbearing potential receiving nirogacestat, 27 of 36 (75%) had adverse events consistent with ovarian dysfunction, which resolved in 20 women (74%).”

Source: [Gounder et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225596/)

<a id="topic-2.1.2.14-13"></a>

### Phase 3 safety: sorafenib

> “Among patients who received sorafenib, the most frequently reported adverse events were grade 1 or 2 events of rash (73%), fatigue (67%), hypertension (55%), and diarrhea (51%).”
> “dose reductions due to toxic effects occurred in 31% (15 of 49) and 11% (4 of 35), respectively.”
> “Adverse events led to a significantly higher rate of discontinuation of the trial regimen in the sorafenib group than in the placebo group (20% vs. no patients).”
> “Grade 3 adverse events that were attributed to the trial regimen by the investigators occurred in 29% of patients in the sorafenib group and 14% of patients in the placebo group.”

Source: [Gounder et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6447029/)

<a id="topic-2.1.2.14-14"></a>

### Company cross-trial comparison of phase 3 objective response rates, with its disclaimer

| Phase 3 trial | Year shown | Regimen | Trial and size | Objective response rate, active | Objective response rate, placebo |
| --- | --- | --- | --- | --- | --- |
| Sorafenib | “2018” | “400mg Once Daily Oral” | “NCT02066181; N=87” | “ORR: 33%” | “ORR: 20%” |
| Nirogacestat | “2023” | “150 mg Twice-Daily Oral” | “DeFi; n=142” | “ORR: 41%” | “ORR: 8%” |
| Varegacestat | “2025” | “1.2mg Once-Daily Oral” | “RINGSIDE; N=156” | “ORR: 56%” | “ORR: 9%” |

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

> “Phase 3 Studies in Desmoid Tumors”
> “FOR ILLUSTRATIVE PURPOSES ONLY: no head-to-head clinical trial has been conducted evaluating varegacestat against nirogacestat or other candidates or products. Differences exist between trial designs and subject characteristics, and strong caution should be exercised when comparing data across unrelated studies.”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.1.2.14-15"></a>

### Company and investigator comparative statements

> “RINGSIDE is the largest and most comprehensive clinical trial conducted to date in patients with desmoid tumors, and the topline results represent the highest objective response rate observed in a randomized clinical trial in this patient population,”
> “These findings demonstrate the potential of varegacestat to offer best-in-class results in a convenient, once-daily, oral medicine that may help patients reclaim their lives.”

Source: [Immunome press release, RINGSIDE topline results (2025)](https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/)

> “VAR demonstrated statistically significant and clinically meaningful antitumor activity and pain relief, achieving the highest ORR reported in a Phase 3 trial of systemic DT therapy, with no new safety signals.”

Source: [Gounder et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.11506)

<a id="topic-2.1.2.14-16"></a>

### Wholesale acquisition cost of nirogacestat, January 2026

| Product | NDC | Dosage form and strength | Wholesale acquisition cost |
| --- | --- | --- | --- |
| OGSIVEO 100 mg | “82448-0100-14” | “Oral Tablet 100 MG” | “$7,746.58” |
| OGSIVEO 150 mg | “82448-0150-14” | “Oral Tablet 150 MG” | “$7,746.58” |

Source: [SpringWorks Connecticut OGSIVEO price disclosure (2026)](https://springworkstx.com/wp-content/uploads/2024/06/CT-Price-Disclosure-Form-2024-v2.pdf)

> “The WAC represents published catalogue or list price and may not represent actual transactional prices.”
> “01/05/2026”

Source: [SpringWorks Connecticut OGSIVEO price disclosure (2026)](https://springworkstx.com/wp-content/uploads/2024/06/CT-Price-Disclosure-Form-2024-v2.pdf)

<a id="topic-2.1.2.14-17"></a>

### Wholesale acquisition cost of nirogacestat at introduction, December 2023, superseded in January 2026

> “OGSIVEO (Nirogacestat) 50mg tablets, 180-ct bottle”
> “12/4/2023”
> “WAC AT INTRODUCTION”
> “$29,000”

Source: [Vermont Attorney General new drug report (2024)](https://ago.vermont.gov/sites/ago/files/2024-08/HCDL%202024%20Q1/VT%20New%20Drug%20Report%20-%2030-Day%20Report.pdf)

<a id="topic-2.1.2.14-18"></a>

### Other products in development for desmoid tumors: zolucatetide

> “With respect to varegacestat, we expect to compete with companies advancing treatments for desmoid tumors, including Merck KGaA (successor to SpringWorks Therapeutics, Inc.) and Parabilis Medicines, Inc.”
> “Parabilis is evaluating the small molecule zolucatetide in a Phase 1/2 study that includes patients with desmoid tumors and plans to initiate a phase 3 registrational trial in 2027.”
> “Desmoid tumor treatments also include surgery, hormonal therapy, cryotherapy, targeted therapy and chemotherapy.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
